Fc Engineered Anti-Human EGFR Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ04] (CAT#: BioBet-C004ZP) Datasheet

Target
EGFR
Isotype
Chimeric (mouse/human)
Description
CDC-enhanced Cetuximabis a Fc-modified anti-EGFR therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Cetuximab, the Fc region of Cetuximab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Metastatic Colorectal Cancer (MCRC)
Metastatic Squamous Cell Carcinoma of the Head and Neck
Advanced squamous cell carcinoma of the head and neck
Classification
Therapeutic antibody; biobetter
Patent
The patents expired in US on 2016-03-02.
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Cetuximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
EGFR
Full Name
epidermal growth factor receptor
Background
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer.
Alternative Names
EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog
Gene ID
UniProt ID
Trade name
Erbitux
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB00002
CAS number
205923-56-4
Antibody Isotype
Chimeric IgG1
Description
Cetuximab is a recombinant human / mouse chimeric epidermal growth factor receptor (EGFR) monoclonal antibody that binds to the epidermal growth factor receptor. It was approved by the US Food and Drug Administration in February 2004 for combination therapy for metastatic colorectal cancer expressing EGFR. Cetuximab is also approved as a single drug for the treatment of patients with metastatic colorectal cancer with EGFR expression intolerance.
Indication
Metastatic Colorectal Cancer (MCRC)
Metastatic Squamous Cell Carcinoma of the Head and Neck
Advanced squamous cell carcinoma of the head and neck
Synonyms
Cetuximab
Cétuximab
Cetuximabum
UNII
PQX0D8J21J

Cetuximab binds to epidermal growth factor receptor (EGFr) on both normal and tumor cells and is widely used to treat metastatic CRC. EGFr is overexpressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGFα, thereby reducing their effect on cell growth and metastasis. Mouse model experiments show that cetuximab can target tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC) and increase antitumor activity.

Cetuximab is used in combination with irinotecan, and is suitable for the treatment of metastatic colorectal cancer expressing EGFR in patients who are difficult to treat with irinotecan-based chemotherapy. Cetuximab monotherapy can be used to treat metastatic colorectal cancer expressing EGFR in patients who are intolerant to irinotecan-based chemotherapy.
Solide Tumors
Metastatic Colorectal Cancer (MCRC)
Metastatic Squamous Cell Carcinoma of the Head and Neck
Advanced squamous cell carcinoma of the head and neck

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK